CN107929292B - Enteral nutrition preparation combining konjac mannan-oligosaccharide and L-glutamine and application - Google Patents
Enteral nutrition preparation combining konjac mannan-oligosaccharide and L-glutamine and application Download PDFInfo
- Publication number
- CN107929292B CN107929292B CN201810003320.0A CN201810003320A CN107929292B CN 107929292 B CN107929292 B CN 107929292B CN 201810003320 A CN201810003320 A CN 201810003320A CN 107929292 B CN107929292 B CN 107929292B
- Authority
- CN
- China
- Prior art keywords
- glutamine
- oligosaccharide
- konjac mannan
- groups
- kmos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 30
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 title claims abstract description 25
- 150000003272 mannan oligosaccharides Chemical class 0.000 title claims abstract description 24
- 230000035764 nutrition Effects 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 229930182816 L-glutamine Natural products 0.000 title claims abstract description 21
- 229920002752 Konjac Polymers 0.000 title claims abstract description 20
- 235000010485 konjac Nutrition 0.000 title claims abstract description 20
- 241001312219 Amorphophallus konjac Species 0.000 title claims abstract description 18
- 235000001206 Amorphophallus rivieri Nutrition 0.000 title claims abstract description 18
- 239000000252 konjac Substances 0.000 title claims abstract description 18
- 229940025902 konjac mannan Drugs 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000002504 physiological saline solution Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 241000700159 Rattus Species 0.000 abstract description 28
- 230000000694 effects Effects 0.000 abstract description 13
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 4
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 6
- 239000004380 Cholic acid Substances 0.000 description 6
- 235000019416 cholic acid Nutrition 0.000 description 6
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 6
- 229960002471 cholic acid Drugs 0.000 description 6
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 235000009200 high fat diet Nutrition 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 108010028554 LDL Cholesterol Proteins 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 241000209524 Araceae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100032487 Beta-mannosidase Human genes 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 description 1
- 108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 108010055059 beta-Mannosidase Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of medicines, and particularly discloses an enteral nutrition preparation combining konjac mannan-oligosaccharide and L-glutamine and application thereof in hyperlipemia nutritional treatment. The method is adopted in the nutrition treatment of model hyperlipidaemia rats, has a certain curative effect, has no toxic or side effect, is simple in preparation method, and wide in application prospect, and the preparation materials are easy to obtain.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to an enteral nutrition preparation combining konjac mannan oligosaccharide and L-glutamine, and also relates to application of the enteral nutrition preparation in hyperlipemia nutrition treatment.
Background
Epidemiological studies have shown that the onset of atherosclerosis and coronary heart disease is closely related to hyperlipidemia, while elevated levels of Triglycerides (TG), Total Cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and reduced levels of high-density lipoprotein cholesterol (HDL-C) are important indicators of hyperlipidemia. The elevation of TC level is one of the important reasons of atherosclerosis, while HDL-C can transport TC in peripheral tissues to liver to decompose into cholic acid, activate lecithin cholesterol acyltransferase, catalyze the esterification reaction of TC, and reduce the serum TC level. The current clinical treatment measures for hyperlipemia mainly comprise the following aspects: a change in lifestyle; lipid-lowering drug therapy; other therapeutic measures include: traditional Chinese medicine lipid-lowering therapy, surgical operation therapy, gene therapy, dialysis therapy and the like. However, the above treatment methods have certain disadvantages due to factors such as patient compliance, side effects of treatment, and difficulty in developing treatment.
Konjak is a tuber of a perennial herb of the genus konjak of the family Araceae. In recent years, domestic and foreign researches prove that konjac mannan oligosaccharide (KGM) extracted from konjac is excellent low-calorie, low-fat and high-cellulose water-soluble dietary fiber and prebiotics, has important regulation effects on nutrition balance, mainly has the functions of relaxing bowel, losing weight and regulating cholesterol metabolism, and has different degrees of curative effects on atherosclerosis, constipation, diabetes, obesity and the like. Because KGM has the characteristics of water absorption, gel property, cohesiveness and low-heat edible property, the KGM can be widely applied to the fields of food processing, health-care products and the like.
At present, research conclusions about the influence of KGM on human glycolipid metabolism, body weight and blood pressure are different at home and abroad, and sample size is small, so the conclusion needs to be obtained by performing Meta analysis on random control tests of a plurality of clinical centers. The mechanism of reducing blood lipid by konjac mannan-oligosaccharide has not been fully elucidated. Because KGM is difficult to digest, KGM is difficult to decompose by enzymes in digestive juice after being ingested into a human body, and is utilized by bifidobacteria after entering the large intestine, thereby promoting the mass proliferation of the bifidobacteria. Bifidobacteria control cholesterol synthesis by controlling the newly formed LDL-C receptor and affecting the activity of hydroxymethylglutaryl-coa reductase to reduce LDL-C content. KGM can also be combined with cholic acid, so that the concentration of cholic acid in liver circulation is reduced, cholesterol is forced to be converted into cholic acid, the KGM and the conjugate of cholic acid are discharged out of a body to prevent the resorption of cholic acid, and the cholesterol is indirectly reduced.
Glutamine (Gln) is essential amino acid for human body, and has effects of promoting protein synthesis, maintaining normal structure and function of small intestine mucous membrane, and enhancing immunity. Glutamine can be effectively supplemented by supplementing LALG because glutamine itself has low hydrolyzability and N (2) -L-alanyl-L-glutamine (LALG) is relatively stable. Glu is a special nutrient and has dual functions of immunity and nutrition: (1) glu is an important carrier for nitrogen transfer among tissues, is an important precursor for synthesizing amino acid, purine and pyrimidine, is an important regulating factor for protein metabolism, has positive correlation between the synthesis rate of body protein and the plasma concentration of Glu, and can obviously enhance the synthesis of body protein and promote positive nitrogen balance by supplementing Glu; (2) glu are rapidly proliferating and differentiating cells, such as: the main energy substances of the intestinal mucosa epithelial cells can promote epithelial regeneration, remove damaged cells, increase the thickness and villus height of the small intestinal mucosa, promote the secretion of s-IgA by plasma cells, coat bacteria in the intestinal lumen, promote the generation of interleukin, gamma-interferon and the like by intestinal wall lamina propria lymphocytes, and have important significance for maintaining the barrier function of the gastrointestinal tract mucosa and preventing enterogenous infection; (3) glu can maintain the oxidation resistance of the organism by supporting the synthesis of glutathione.
At present, the treatment of hyperlipidemia mainly comprises life style adjustment and drug therapy, but hyperlipidemia patients usually have metabolic diseases such as obesity, non-alcoholic fatty liver disease, diabetes and the like, so comprehensive treatment from multiple aspects is needed, the applicant performs nutritional intervention treatment on model hyperlipidemia rats through combination of konjac mannan-oligosaccharide and L-glutamine to obtain a certain curative effect, and the used nutritional preparations are all food-borne, have no toxic or side effect, and are worthy of popularization and application.
Disclosure of Invention
Aiming at the defects in the prior art, the invention aims to provide an enteral nutrition preparation combining konjac mannan oligosaccharide and L-glutamine and application thereof.
In order to achieve the purpose, the invention adopts the following technical measures:
first, the present invention provides an enteral nutrition preparation combining konjac mannan-oligosaccharide and L-glutamine, which is a mixed physiological saline solution of konjac mannan-oligosaccharide and L-glutamine; further, the composition of the enteral nutrition preparation is as follows:
the amount of the components
16 parts by weight of konjac mannan oligosaccharide
3 parts by weight of L-glutamine
100 parts by volume of physiological saline (0.9% aqueous sodium chloride solution),
the unit ratio of the parts by weight to the parts by volume is g/mL.
Compared with the prior art, the enteral nutrition preparation has the following advantages and beneficial effects:
1. at present, the incidence rate of metabolic diseases such as national and even global hyperlipidemia, obesity, type 2 diabetes, non-alcoholic fatty liver disease and the like is increasing day by day, the treatment means is mainly medical means such as medicines and operations except the change of life style, and the existing treatment methods have the characteristics of multiple side effects, large difficulty in development, poor patient compliance and the like. The invention provides a food-originated active ingredient for treating metabolic diseases such as hyperlipidemia and the like from the nutrition perspective.
2. The konjac mannan oligosaccharide is functional oligosaccharide obtained by β -1,4 mannase action of glucomannan extracted from konjac, and has the effects of regulating intestinal flora, enhancing immunity, regulating blood sugar and blood fat.
3. From the aspect of nutrition treatment, the nutritional preparation is food-borne, has no toxic or side effect on human bodies, high safety, good patient compliance and small development difficulty, and is beneficial to popularization and application.
Detailed Description
The sources of the raw materials of the enteral nutrition preparation prepared by the invention are as follows: konjac mannan-oligosaccharides were purchased from enrzeya tianjia biotechnology limited; L-Glutamine was purchased from Guangzhou Green interest Nutrition, Inc.; the physiological saline was 0.9% aqueous sodium chloride solution.
Example 1
A preparation method of an enteral nutrition preparation combining konjac mannan-oligosaccharide and L-glutamine comprises the following steps:
dissolving 16g konjac mannan oligosaccharide in 100mL normal saline, and adding 3g L-glutamine to obtain the final product.
Example 2
Therapeutic effect of an enteral nutritional preparation combining konjac mannan-oligosaccharide and L-glutamine on model hyperlipidemic rats:
1. influence of intestinal nutrition preparation combining konjac mannan-oligosaccharide and L-glutamine on body quality of model hyperlipidemic rats
Grouping introduction of rats: the control group is a negative control group; the model group is a hyperlipemia group without intervention, and the KMOS-L is a low-dose KMOS experimental group; KMOS-M is a middle-dose KMOS experimental group; KMOS-H is a high-dose KMOS experimental group; KMOS-HL was a combination of high-dose KMOS and L-glutamine. The groups except the control group were model groups fed with high-fat diet. As shown in table 1, there was no significant difference in body mass between the initial experiment and the end of week 4, at the end of week 5, i.e. the molding period, the body mass of rats in the 5 groups of high fat diet groups was significantly higher than that of the control group, and there was no statistical significance in the difference in body mass between rats in the 5 groups of high fat diet groups; at the end of the 10 th week, i.e. the expected end of the nutrition, the body mass of the rats in the 5 groups of high-fat diet groups is still significantly higher than that of the control group, and the body mass of the rats in the 4 groups of KMOS experimental groups has a tendency to decrease compared with that of the model group, but the difference is not statistically significant.
TABLE 1 comparison of body masses of rats of each group
Note: compared with the control group, the compound of the formula,*P<0.05
2. influence of intestinal nutrition preparation combining konjac mannan-oligosaccharide and L-glutamine on blood lipid level of model hyperlipidemic rat
As shown in table 2, the serum TC content of rats in 5 high-fat diet groups was significantly higher than that of the control group, and the HDL-C content was significantly lower than that of the control group at the end of 5 weeks; the TG level has a rising trend compared with a control group, but the difference has no statistical significance; comparison of LDL-C levels was statistically insignificant between the 6 groups. At the end of 10 weeks, the serum TC levels of the rats in the KMOS-M, KMOS-H and KMOS-HL groups were significantly lower than those in the model group, and the comparative difference between the groups was statistically significant, but not significantly different from that in the control group; the serum TG level of rats in the 4 experimental groups is obviously lower than that of the model group, and the comparative difference between the groups has statistical significance, but the comparative difference with the control group has no statistical significance.
TABLE 2 comparison of blood lipid levels in rats of various groups
Note: compared with the control group, the compound of the formula,*P<0.05; in comparison with the set of models,#P<0.05
3. an enteral nutritional preparation combined with konjac mannan-oligosaccharide and L-glutamine for treating rat with model hyperlipidemia has effects of fasting blood glucose and insulin level
As shown in Table 3, at the end of 5 weeks, the fasting blood glucose and insulin of rats in 5 groups of high-fat diet groups are significantly higher than those in the control group, and the comparison difference between the groups has statistical significance. At the end of 10 weeks, the fasting blood glucose of rats in 5 groups of high-fat feed groups is still obviously higher than that of the control group, and the comparison difference between the groups has statistical significance; the serum insulin of rats in the 5 groups of high-fat feed groups is obviously higher than that of rats in the control group, and the comparative difference between the groups has statistical significance.
TABLE 3 comparison of fasting plasma glucose and insulin levels in rats of various groups
Note: compared with the control group, the compound of the formula,*P<0.05; in comparison with the set of models,#P<0.05
4. effect of intestinal nutrition preparation combining konjac mannan-oligosaccharide and L-glutamine on serum lipid peroxidation index and antioxidant enzyme level of rat with model hyperlipidemia
At the end of 5 weeks, the MDA content of the rat serum of the 5 groups of high-fat feed groups is obviously higher than that of the control group, and the comparison difference among the groups has statistical significance; the content of the serum SOD in the KMOS-M, KMOS-H and KMOS-HL groups is obviously lower than that in the control group, and the comparison difference between the groups has statistical significance. At the end of 10 weeks, the content of the KMOS-M, KMOS-H and KMOS-HL group serum MDA is significantly lower than that of the model group, and the comparative difference between the groups has statistical significance, but has no statistical significance compared with the control group; the serum GSH and SOD of the KMOS-HL rat are obviously higher than those of the control group, and the serum GSH of the KMOS-HL rat is also obviously higher than those of the model group and the KMOS-H group, which are shown in the table 4. Although the blood lipid content of the KMOS-HL group rats is not obviously reduced compared with the KMOS-H group, the oxidative stress state of the KMOS-HL group rats is obviously improved compared with the KMOS-H group.
TABLE 4 comparison of serum lipid peroxidation index and antioxidant enzyme levels in various groups of rats
Note: compared with the control group, the compound of the formula,*P<0.05; in comparison with the set of models,#P<0.05; in comparison with the group of KMOS-H,ΔP<0.05。
Claims (1)
1. an enteral nutrition preparation combining konjac mannan-oligosaccharide and L-glutamine, wherein the enteral nutrition preparation is a mixed physiological saline solution of the konjac mannan-oligosaccharide and the L-glutamine;
the enteral nutritional formulation consists of:
the amount of the components
16 parts by weight of konjac mannan oligosaccharide
3 parts by weight of L-glutamine
100 parts by volume of the normal saline is added,
the unit ratio of the parts by weight to the parts by volume is g/mL.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710945538 | 2017-10-12 | ||
| CN2017109455383 | 2017-10-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107929292A CN107929292A (en) | 2018-04-20 |
| CN107929292B true CN107929292B (en) | 2020-04-10 |
Family
ID=61937331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810003320.0A Active CN107929292B (en) | 2017-10-12 | 2018-01-03 | Enteral nutrition preparation combining konjac mannan-oligosaccharide and L-glutamine and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107929292B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103468766B (en) * | 2013-09-18 | 2015-07-01 | 恩施天天佳生物科技有限公司 | Preparation method of high-purity mannan oligosaccharide |
-
2018
- 2018-01-03 CN CN201810003320.0A patent/CN107929292B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| Effects of dietary supplementation of glutamine and mannan oligosaccharides on plasma;Lu Jin, et al.;《Journal of Applied Animal Research》;20141231;第42卷(第2期);160-165 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107929292A (en) | 2018-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5498698B2 (en) | New uses of white jellyfish miscellaneous polysaccharides or their extracts | |
| CN110150669B (en) | Probiotic composition suitable for diabetic patients and application thereof | |
| CN114146120B (en) | Composition microcapsule for preventing and treating atrophic gastritis and preparation method thereof | |
| JPH03151854A (en) | Composition for improving intestinal environment | |
| CN110710660A (en) | Blood sugar lowering composition and dietary supplement containing bitter gourd powder | |
| EP2635130B1 (en) | Composition of purified soluble mannans for dietary supplements and methods of use thereof | |
| CN111228316B (en) | Composite probiotics for improving diabetes | |
| CN114452308A (en) | Probiotics protective agent, microecological preparation prepared from same and application of probiotics protective agent | |
| CN107929292B (en) | Enteral nutrition preparation combining konjac mannan-oligosaccharide and L-glutamine and application | |
| JPWO2017159647A1 (en) | Felicaribacterium spp. | |
| CN110679949A (en) | Weight-losing composition and preparation method thereof | |
| CN111773252B (en) | Prebiotic composition for efficiently reducing blood sugar, blood fat and body weight of type 2 diabetes patients | |
| CN113116941B (en) | Probiotics and prebiotics composite preparation capable of relieving type 2 diabetes and preparation method thereof | |
| CN111280453B (en) | Preparation method of antrodia water-insoluble dietary fiber | |
| DK2865278T3 (en) | Binder fat obtained from biomass, derived from beer production | |
| CN113951328A (en) | A nutritional food for lowering blood sugar and reducing blood lipid, and its preparation method | |
| CN101199492A (en) | Application of oligomerization xylose and xylito in coating slice coating | |
| CN111265627B (en) | Sea cucumber polysaccharide composition for regulating intestinal flora and preparation method and application thereof | |
| CN118222437A (en) | Lactobacillus rhamnosus, fungus powder and application thereof in hypoglycemic and lipid-lowering products | |
| JP2006117566A (en) | Saccharometabolism-ameliorating agent | |
| CN117987331A (en) | Probiotic composition containing lactobacillus paracasei Glory LP16 and application of probiotic composition in weight-losing and lipid-lowering products | |
| CN114304631A (en) | Blood glucose reducing nutritional supplement and preparation method and application thereof | |
| CN113713079A (en) | Intervention preparation capable of directionally inducing and increasing quantity of intestinal clostridium butyricum | |
| CN118272471A (en) | Hawthorn pectin oligosaccharide and preparation method and application thereof | |
| CN115029284A (en) | Active probiotics and application thereof in food |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |